Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    Open Studies | "Leukemia, Hairy Cell"
Show Display Options
Rank Status Study
21 Recruiting Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Lymphoid Leukemia
Interventions: Drug: Dasatinib;   Other: laboratory biomarker analysis
22 Recruiting Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Multiple;   Mycosis Fungoides;   Hodgkin's Lymphoma;   Multiple Myeloma
Intervention: Drug: Dasatinib
23 Recruiting A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Conditions: Relapsed Lymphoid Malignancy;   Refractory Lymphoid Malignancy
Intervention: Drug: AGS67E

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-23) Next Page   
Study has passed its completion date and status has not been verified in more than two years.